BioNTech SE - ADR

XNAS:BNTX 4:00:00 PM EDT

108.77

+0.52 (+0.48%)

: $107.50 -1.27 (-1.17%)

Market Cap (Intraday)	26.28B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$921.14 Million
Adjusted EPS	-$0.20

See more estimates

10-Day MA	$111.07
50-Day MA	$101.76
200-Day MA	$104.16

See more pivots

BioNTech SE - ADR Stock, XNAS:BNTX

An der Goldgrube 12, Mainz, Rheinland-Pfalz 55131

Germany

Phone: +49.6131.9084.0

Number of Employees: 6772

http://www.biontech.de

Description

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.